Products - Metastases | Topic | NICE

Showing 7 products

Date | Title

Product type: GuidanceRemove ‘Product type: Guidance’ filter
Status: PublishedRemove ‘Status: Published’ filter
New and updated: New in the last 6 monthsRemove ‘New and updated: New in the last 6 months’ filter

Enfortumab vedotin for treating locally advanced or metastatic urothelial cancer after 2 therapies [ID3845]
Product type:
Guidance
Programme:
Technology appraisal guidance
Expected publication date:
15 June 2022
Encorafenib with binimetinib for treating BRAF V600E mutation-positive advanced non-small-cell lung cancer (TA1150)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
6 May 2026
Nivolumab with chemotherapy for untreated unresectable or metastatic urothelial cancer (terminated appraisal) (TA1141)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
17 March 2026
Bevacizumab (originator and biosimilars) with fluoropyrimidine-based chemotherapy for metastatic colorectal cancer (TA1136)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
25 February 2026
Talazoparib with enzalutamide for untreated hormone-relapsed metastatic prostate cancer (TA1130)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
11 February 2026
Amivantamab with lazertinib for untreated EGFR mutation-positive advanced non-small-cell lung cancer (TA1122)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
21 January 2026
Avelumab with axitinib for untreated advanced renal cell carcinoma (TA1120)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
8 January 2026